Tetzlaff WF, Meroño T, Menafra M, Martin M, Botta E, Matoso MD, Sorroche P, De Paula JA, Boero LE, Brites F. Markers of inflammation and cardiovascular disease in recently diagnosed celiac disease patients. World J Cardiol 2017; 9(5): 448-456 [PMID: 28603593 DOI: 10.4330/wjc.v9.i5.448]
Corresponding Author of This Article
Laura E Boero, PhD, Department of Clinical of Biochemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, INFIBIOC, CONICET, Junín 956 (1113), Buenos Aires C1113AAD, Argentina. laura.boero@hotmail.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Tetzlaff WF, Meroño T, Menafra M, Martin M, Botta E, Matoso MD, Sorroche P, De Paula JA, Boero LE, Brites F. Markers of inflammation and cardiovascular disease in recently diagnosed celiac disease patients. World J Cardiol 2017; 9(5): 448-456 [PMID: 28603593 DOI: 10.4330/wjc.v9.i5.448]
World J Cardiol. May 26, 2017; 9(5): 448-456 Published online May 26, 2017. doi: 10.4330/wjc.v9.i5.448
Markers of inflammation and cardiovascular disease in recently diagnosed celiac disease patients
Walter F Tetzlaff, Tomás Meroño, Martin Menafra, Maximiliano Martin, Eliana Botta, Maria D Matoso, Patricia Sorroche, Juan A De Paula, Laura E Boero, Fernando Brites
Walter F Tetzlaff, Tomás Meroño, Martin Menafra, Maximiliano Martin, Eliana Botta, Laura E Boero, Fernando Brites, Department of Clinical of Biochemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, INFIBIOC, CONICET, Buenos Aires C1113AAD, Argentina
Maria D Matoso, Juan A De Paula, Service of Gastroenterology, Buenos Aires Italian Hospital, Buenos Aires C11000ABC, Argentina
Patricia Sorroche, Central Laboratory, Buenos Aires Italian Hospital, Buenos Aires C11000ABC, Argentina
Author contributions: Tetzlaff WF performed biochemical determinations, data collection and data analysis; Meroño T and Martin M analyzed the data; Menafra M, Botta E and Sorroche P performed the biochemical determinations; Matoso MD and De Paula JA contributed in the recruitment of patients and clinical studies; Boero LE and Brites F contributed equally in the design of research and revised the article critically for important intellectual content.
Supported by CONICET, No. PIP 11220110100516; and University of Buenos Aires, No. UBACyT 20020150100054BA.
Institutional review board statement: The study was reviewed and approved by the Ethical Committees from School of Pharmacy and Biochemistry, University of Buenos Aires.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: There are no conflicts of interest to report.
Data sharing statement: The technical appendix is available from the corresponding author laura.boero@hotmail.com.
Correspondence to: Laura E Boero, PhD, Department of Clinical of Biochemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, INFIBIOC, CONICET, Junín 956 (1113), Buenos Aires C1113AAD, Argentina. laura.boero@hotmail.com
Telephone: +54-11-59508654 Fax: +54-11-45083645
Received: November 24, 2016 Peer-review started: November 25, 2016 First decision: January 16, 2017 Revised: March 3, 2017 Accepted: April 6, 2017 Article in press: April 10, 2017 Published online: May 26, 2017 Processing time: 177 Days and 6.2 Hours
Core Tip
Core tip: Given that data about the presence of metabolic alterations and atherogenic risk factors in celiac disease are scarce and contradictory, we aimed to investigate carbohydrate metabolism, lipoprotein profile and inflammatory status in patients with celiac disease (CD). Patients presented higher insulin levels, Homeostasis Model Assessment-Insulin Resistance index, apo B/apo A-I ratio and High-sensitivity C reactive protein concentration, as well as lower Quantitative Sensitive Check index index, high density lipoprotein-cholesterol and apo A-I levels in comparison with sex and aged-matched healthy controls. Persistence of these alterations through long periods of time in a chronic pathologic condition, as it is the case with CD, would constitute a high risk of developing atherosclerotic cardiovascular disease.
